Takeda making case for SC form of Entyvio

22 October 2018

Entyvio (vedolizumab), Takeda’s (TYO: 4502) gut-selective biologic that is approved as an intravenous (IV) formulation for ulcerative colitis (UC) and Crohn’s disease (CD), could soon become available in subcutaneous (SC) form.

This comes after Takeda presented Phase III data from the Phase III VISIBLE 1 trial at the 2018 United European Gastroenterology (UEG) Week congress in Vienna, which showed the effectiveness of the SC form for maintenance therapy in adults with moderately to severely active UC who achieved clinical response at week 6 following two doses of open-label Entyvio IV therapy.

At week 52, a statistically-significant proportion of patients receiving Entyvio SC achieved clinical remission compared to patients receiving placebo.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK